Eligible patients receive trastuzumab emtansine 3.6mg/kg Q3W. The treatment period will continue every 21 days for up to 2 years as long as subjects are receiving benefit from treatment and have not h
Sponsors
Funakoshi Takeru
Conditions
HER2-positive advanced extramammary Paget's disease
Other disease of skin or skin tissueHER2-positive advanced paget disease affecting scrotum and Penis
Other disease of skin or skin tissue